NCT03061981View on ClinicalTrials.gov

A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 29, 2017

Primary Completion Date

October 11, 2017

Study Completion Date

October 11, 2017

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Placebo

After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period.

DRUG

Metformin

Subjects in the IE cohort will receive 500 mg metformin (IR formulation) at 12 hours on Day 1 and a single oral dose of the IMP with 500 mg metformin (IR formulation) after an overnight fast on Day 1, in Treatment Period 2.

DRUG

DA-1241

After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period .

Trial Locations (1)

21225

Early Phase Clinical Unit, Baltimore

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT03061981 - A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects | Biotech Hunter | Biotech Hunter